0
Home
News
Directory
E-newsletter
Magazine
Events
Data
AgReport
Subscribe
Eden updates progress on approval of 3AEY in Southern EU
Dec. 22, 2014
Eden Research plc
United KingdomFollow
United KingdomEden Research plc, the AIM listed natural micro-encapsulation company, announced that it has commented on the draft Registration Report from the regulatory authorities in Malta in relation to its review of the application for the authorisation of 3AEY, Eden’s agrochemical product (three terpenes as ais) which is used to tackle botrytis, a fungal disease affecting many plants, including grapes.
The Company has provided comprehensive responses to points raised by the Maltese authorities. The Maltese authorities will next collate all comments received and then advise Eden whether or not all of the information that has been submitted by Eden is sufficient for authorisation of 3AEY. Once authorisation has been given by Malta, the remaining Southern EU zone member states will have 120 days in which to issue their authorisations. Eden, its advisors and its licensees fully expect authorisation in due course, following the processes and requirements of the regulatory authorities.
Sean Smith, Chief Executive Officer of Eden, said: “Whilst the process for registering plant protection products in Europe is onerous and lengthy, particularly given the low risk nature of 3AEY, it is designed to protect the environment and consumers and will ultimately lead to Eden and its partners, such as Sipcam and Sumi Agro France, having a strong competitive position in the market, resulting in royalties to Eden.
“Our partners understand these processes very well and are clearly comfortable with our progress, hence the recently-announced licence agreements and further deals which we expect to announce in due course. Furthermore, we are leveraging our partners’ expertise and strengths to help secure final regulatory authorisation for 3AEY as quickly as possible.”
Source: Eden Research plc
More from AgroNews
Change
Hot TopicSubscribe
| Subscribe Email: | * | |
| Name: | ||
| Mobile Number: | ||
Comment
0/1200
NEWSLETTER